immuno-oncology

News

Gilead’s CD47 woes continue, this time in solid tumours

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug

News

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac

News

BioNTech adds CAR-T manufacturing with $250m Autolus deal

Germany’s BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therap

News

First patient treated with Moderna's PD-1/IDO1 cancer shot

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets th

News

FDA sets date for Adaptimmune’s sarcoma drug verdict

The FDA is due to decide by 4th August whether to approve Adaptimmune’s engineered T-cell therapy for advanced synovial sarcoma, afamitresgene autoleucel (afami-cel), afte

News

Keytruda improves survival in early-stage kidney cancer

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c

Gilead’s CD47 woes continue, this time in solid tumours

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

BioNTech adds CAR-T manufacturing with $250m Autolus deal

First patient treated with Moderna's PD-1/IDO1 cancer shot

FDA sets date for Adaptimmune’s sarcoma drug verdict

Keytruda improves survival in early-stage kidney cancer

Bayer gets swift review for Kerendia in type 1 diabetes

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks